NEALS 2022 poster: Discovery and development of the 15-lipoxygenase inhibitor utreloxastat to reduce ferroptosis-induced injury for ALS and neurodegenerative diseases
This poster, presented at NEALS 2022, shows the preclinical results of utreloxastat in amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases
Learn more about utreloxastat, a novel 15-lipoxygenase inhibitor
Explore the in vitro data on utreloxastat, which targets ferroptosis and prevents ferroptotic cell death
Discover the effects of utreloxastat in vivo on lowering disease severity and its therapeutic potential in patients with ALS
Utreloxastat is an investigational drug currently in development for ALS
This poster was developed and funded by PTC Therapeutics for NEALS 2022. It is not part of the official program at NEALS 2022.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-ALS-2300003 | February 2023
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.